CN108864093A - 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 - Google Patents

取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 Download PDF

Info

Publication number
CN108864093A
CN108864093A CN201810842686.7A CN201810842686A CN108864093A CN 108864093 A CN108864093 A CN 108864093A CN 201810842686 A CN201810842686 A CN 201810842686A CN 108864093 A CN108864093 A CN 108864093A
Authority
CN
China
Prior art keywords
compound
alkyl
mmol
halogen
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810842686.7A
Other languages
English (en)
Chinese (zh)
Inventor
C.F.格林
T.P.勒博德
B.T.斯雷曼
J.M.兹夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN108864093A publication Critical patent/CN108864093A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201810842686.7A 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 Pending CN108864093A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
US61/780378 2013-03-13
CN201480027437.2A CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480027437.2A Division CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Publications (1)

Publication Number Publication Date
CN108864093A true CN108864093A (zh) 2018-11-23

Family

ID=50487148

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810842686.7A Pending CN108864093A (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201480027437.2A Active CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201910948604.1A Active CN110669052B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201480027437.2A Active CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201910948604.1A Active CN110669052B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Country Status (38)

Country Link
US (5) US9611277B2 (https=)
EP (4) EP4272824A3 (https=)
JP (1) JP6275815B2 (https=)
KR (1) KR102209424B1 (https=)
CN (3) CN108864093A (https=)
AR (1) AR095423A1 (https=)
AU (2) AU2014248680B2 (https=)
BR (1) BR112015022294B1 (https=)
CA (1) CA2904618C (https=)
CL (1) CL2015002609A1 (https=)
CR (2) CR20210523A (https=)
CY (3) CY1120024T1 (https=)
DK (2) DK3363438T3 (https=)
EA (1) EA029276B1 (https=)
ES (3) ES2950032T3 (https=)
HR (3) HRP20180303T1 (https=)
HU (3) HUE047592T2 (https=)
IL (2) IL240466B (https=)
JO (1) JOP20140092B1 (https=)
LT (2) LT3363438T (https=)
ME (2) ME03572B (https=)
MX (2) MX361529B (https=)
MY (1) MY183725A (https=)
NI (1) NI201500130A (https=)
NO (1) NO3107630T3 (https=)
PE (1) PE20151599A1 (https=)
PH (1) PH12015501929B1 (https=)
PL (3) PL3363438T3 (https=)
PT (2) PT2970314T (https=)
RS (3) RS59466B1 (https=)
SG (1) SG11201507415QA (https=)
SI (2) SI3363438T1 (https=)
SM (3) SMT201900655T1 (https=)
TW (1) TWI621618B (https=)
UA (1) UA118669C2 (https=)
UY (1) UY35409A (https=)
WO (1) WO2014165070A1 (https=)
ZA (1) ZA201507562B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
WO2015131773A1 (zh) 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
AU2015314851B2 (en) * 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
US10668066B2 (en) 2015-08-14 2020-06-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
WO2018098361A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
AU2018326734B2 (en) 2017-09-01 2023-08-17 Chronos Therapeutics Limited Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
AU2019395255B2 (en) * 2018-12-14 2025-02-27 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CN101965343A (zh) * 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
AU2003202753A1 (en) 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1599483A1 (en) 2003-02-21 2005-11-30 Pharmacia & Upjohn Company LLC Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo 2.2.1 heptane- 7-carboxylate, intermediates, and process to prepare and isolate them
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
CA2669060A1 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd Piperidine compounds
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
SI2170864T1 (sl) 2007-07-17 2012-04-30 Bristol Myers Squibb Co Piridon gpr119g proteinsko povezani receptorski antagonisti
CN101903372B (zh) 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
CN102015645B (zh) 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
JP2012510494A (ja) 2008-12-02 2012-05-10 グラクソ グループ リミテッド Ｎ−｛［（ｉｒ、４ｓ、６ｒ）−３−（２−ピリジニルカルボニル）−３−アザビシクロ［４．１．０］ヘプタ−４−イル］メチル｝−２−ヘテロアリールアミン誘導体およびその使用
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
WO2011087812A1 (en) 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2911675A4 (en) 2012-10-23 2016-06-01 Merck Sharp & Dohme 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
WO2014075392A1 (en) 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
EP3102569A1 (en) 2014-02-06 2016-12-14 AbbVie Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CN101965343A (zh) * 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物

Also Published As

Publication number Publication date
AR095423A1 (es) 2015-10-14
HUE047592T2 (hu) 2020-05-28
HRP20192032T1 (hr) 2020-02-07
AU2014248680A1 (en) 2015-08-27
ES2760564T3 (es) 2020-05-14
PT2970314T (pt) 2018-03-05
US20170015651A1 (en) 2017-01-19
PL3363438T3 (pl) 2020-02-28
AU2018204835A1 (en) 2018-07-19
CN105308048B (zh) 2019-10-08
US20170204096A1 (en) 2017-07-20
CY1120024T1 (el) 2018-12-12
SI2970314T1 (en) 2018-02-28
UA118669C2 (uk) 2019-02-25
PH12015501929A1 (en) 2016-01-04
HRP20180303T1 (hr) 2018-03-23
EP4272824A2 (en) 2023-11-08
ZA201507562B (en) 2019-04-24
CL2015002609A1 (es) 2016-03-28
CR20210523A (es) 2021-11-19
WO2014165070A1 (en) 2014-10-09
SI3363438T1 (sl) 2019-11-29
US9845333B2 (en) 2017-12-19
MX361529B (es) 2018-12-07
US9447117B2 (en) 2016-09-20
BR112015022294B1 (pt) 2022-09-13
CY1126106T1 (el) 2023-11-15
MX368466B (es) 2019-10-03
HUE036193T2 (hu) 2018-06-28
NI201500130A (es) 2015-11-30
PL2970314T3 (pl) 2018-05-30
HK1219725A1 (en) 2017-04-13
IL240466B (en) 2019-03-31
SG11201507415QA (en) 2015-10-29
PE20151599A1 (es) 2015-11-12
US10183953B2 (en) 2019-01-22
EP3363438B1 (en) 2019-09-18
CN110669052A (zh) 2020-01-10
UY35409A (es) 2014-09-30
IL240466A0 (en) 2015-09-24
SMT201900655T1 (it) 2020-01-14
CY1122392T1 (el) 2021-01-27
SMT202300223T1 (it) 2023-09-06
ES2659397T3 (es) 2018-03-15
CR20150433A (es) 2015-10-26
JP6275815B2 (ja) 2018-02-07
BR112015022294A2 (pt) 2017-07-18
HRP20230633T1 (hr) 2023-09-29
CA2904618C (en) 2021-12-07
EP3622956B9 (en) 2023-09-27
US20160052939A1 (en) 2016-02-25
RS59466B1 (sr) 2019-11-29
NO3107630T3 (https=) 2018-01-06
CA2904618A1 (en) 2014-10-09
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
MY183725A (en) 2021-03-10
KR102209424B1 (ko) 2021-01-29
EP3622956B1 (en) 2023-06-07
RS64551B1 (sr) 2023-10-31
MX2015011815A (es) 2016-11-07
ES2950032T3 (es) 2023-10-04
ME03572B (me) 2020-07-20
SMT201800056T1 (it) 2018-03-08
TW201446757A (zh) 2014-12-16
US20140275118A1 (en) 2014-09-18
ME03011B (me) 2018-10-20
DK2970314T3 (en) 2018-02-26
EA029276B1 (ru) 2018-03-30
EP2970314B1 (en) 2017-12-13
CN105308048A (zh) 2016-02-03
TWI621618B (zh) 2018-04-21
EP4272824A3 (en) 2024-01-10
JP2016512535A (ja) 2016-04-28
IL264606A (en) 2019-02-28
NZ710872A (en) 2020-10-30
RS56875B1 (sr) 2018-04-30
LT2970314T (lt) 2018-02-12
HUE063608T2 (hu) 2024-01-28
PT3363438T (pt) 2019-12-11
AU2014248680B2 (en) 2018-07-26
CN110669052B (zh) 2022-10-11
US9611277B2 (en) 2017-04-04
US20150174129A1 (en) 2015-06-25
KR20150126694A (ko) 2015-11-12
EP3363438A1 (en) 2018-08-22
AU2018204835B2 (en) 2019-08-08
US8969352B2 (en) 2015-03-03
DK3363438T3 (da) 2019-11-11
LT3363438T (lt) 2019-11-11
RS64551B9 (sr) 2023-12-29
PL3622956T3 (pl) 2023-09-18
EP3622956C0 (en) 2023-06-07
JOP20140092B1 (ar) 2021-08-17
PH12015501929B1 (en) 2016-01-04
EP3622956A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
CN105308048B (zh) 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN105209468B (zh) 取代的7‑氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN107108566B (zh) 取代的2-氮杂双环化合物以及它们作为食欲素受体调节剂的用途
CN105228995A (zh) 取代的哌啶化合物以及它们作为食欲素受体调节剂的用途
HK40020928A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK40020928B (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK1261216A1 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
NZ710872B2 (en) Substituted 2-azabicycles and their use as orexin receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261216

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1261216

Country of ref document: HK